Understanding how a virus affects cancer cell behavior to improve treatment options
Resolving viral oncoprotein control of terminal cell fates to limit Epstein-Barr virus-driven lymphoproliferation
This study is looking at how the Epstein-Barr virus affects certain immune cells in people with weakened immune systems, with the hope of finding better treatments for cancers related to this virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10864163 on NIH RePORTER |
What this research studies
This research investigates the Epstein-Barr virus (EBV), which can lead to various cancers, particularly in individuals with weakened immune systems. By using advanced single-cell techniques, the study aims to uncover how EBV oncoproteins influence the behavior of infected B cells, which can result in cancer. The goal is to better understand the interactions between the virus and host cells, ultimately leading to the development of more effective therapies for EBV-related lymphomas. Patients may benefit from insights that could improve treatment strategies for these cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with EBV-related lymphomas, particularly those with compromised immune systems.
Not a fit: Patients with cancers not associated with Epstein-Barr virus or those without any viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively target EBV-related cancers.
How similar studies have performed: Previous research has shown promising results in understanding viral interactions with host cells, indicating potential for success in this area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Sorelle, Elliott Daniel — University of Michigan at Ann Arbor
- Study coordinator: Sorelle, Elliott Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.